ARS Pharmaceuticals, Inc. SPRY Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Operating margin | -212.9%— | —— | -225,066.7%-222,368pp | -2,698.8%— | |
| Net margin | -203.3%-212pp | 9%+181,226pp | -181,216.7%-178,581pp | -2,635.4%— | |
| EBITDA margin | -211.3%-157pp | -54%+224,769pp | -224,823.3%-222,158pp | -2,664.9%— | |
| Free cash flow margin | -203.1%-218pp | 14.6%+198,151pp | -198,136.7%-195,076pp | -3,060.6%— | |
| Returns | |||||
| Return on equity | -92.3%-95.6pp | 3.3%+24.9pp | -21.6%— | —— | |
| Return on assets | -50.5%-53.2pp | 2.7%+23.9pp | -21.1%-0.9pp | -20.2%— | |
| Return on invested capital | -95.6%-70.2pp | -25.4%+35.2pp | -60.6%— | —— | |
| Efficiency | |||||
| Asset turnover | 0.2×-0.1× | 0.3×+0.3× | 0×0.0× | 0×0.0× | |
| Liquidity | |||||
| Current ratio | 7.3×-7.0× | 14.3×-82.7× | 96.9×+45.9× | 51×+43.6× | |
| Quick ratio | 6.7×-7.3× | 14×-82.9× | 96.9×+45.9× | 51×+43.6× | |
| Cash ratio | 1.1×-1.1× | 2.2×-27.5× | 29.7×-9.0× | 38.7×+31.3× | |
| Leverage | |||||
| Debt-to-equity | 0.8×+0.8× | 0×0.0× | 0×0.0× | 0×— | |
| Debt-to-assets | 0.3×+0.3× | 0×0.0× | 0×0.0× | 0×-0.2× | |
| Per Share | |||||
| Book value per share | $1.16-53.8% | $2.51+3.5% | $2.42-64.5% | $6.83+731% | |
| Valuation | |||||
| Market capitalization | $796.41M-48.7% | $1.03B+94.1% | $528.35M-34.1% | $801.81M+28.4% | |
| Enterprise value | $868.61M-42.6% | $974.53M+113% | $457.66M-22.7% | $591.77M+2.9% | |
| Price / sales | 8.1×-7.9× | 11.5×-17,600× | 17,611.8×+17,003× | 609.3×+496× | |
| Price / book | 13×+6.2× | 4×+1.7× | 2.3×-0.6× | 2.9×— | |
| EV / sales | 8.8×-6.8× | 10.9×-15,244× | 15,255.2×+14,806× | 449.7×+345× | |
| Free cash flow yield | -22%-20.7pp | 1.3%+12.5pp | -11.3%-6.2pp | -5%— | |
| Earnings yield | -24.9%-23.8pp | 0.8%+11.1pp | -10.3%-6.0pp | -4.3%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do ARS Pharmaceuticals, Inc.'s ratios come from?
- Every ratio is computed from ARS Pharmaceuticals, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
